EP2334302B1 - Dosage forms for weakly ionizable compounds - Google Patents
Dosage forms for weakly ionizable compoundsInfo
- Publication number
- EP2334302B1 EP2334302B1 EP09792369.2A EP09792369A EP2334302B1 EP 2334302 B1 EP2334302 B1 EP 2334302B1 EP 09792369 A EP09792369 A EP 09792369A EP 2334302 B1 EP2334302 B1 EP 2334302B1
- Authority
- EP
- European Patent Office
- Prior art keywords
- dosage forms
- ionizable compounds
- weakly ionizable
- weakly
- compounds
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn - After Issue
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
- A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pulmonology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Pain & Pain Management (AREA)
- Urology & Nephrology (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Vascular Medicine (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US9549308P | 2008-09-09 | 2008-09-09 | |
US16199209P | 2009-03-20 | 2009-03-20 | |
PCT/US2009/056362 WO2010030667A2 (en) | 2008-09-09 | 2009-09-09 | Dosage forms for weakly ionizable compounds |
Publications (2)
Publication Number | Publication Date |
---|---|
EP2334302A2 EP2334302A2 (en) | 2011-06-22 |
EP2334302B1 true EP2334302B1 (en) | 2018-03-21 |
Family
ID=41667166
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP09792369.2A Withdrawn - After Issue EP2334302B1 (en) | 2008-09-09 | 2009-09-09 | Dosage forms for weakly ionizable compounds |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP2334302B1 (en) |
JP (1) | JP5661630B2 (en) |
CA (1) | CA2735660C (en) |
MX (1) | MX340669B (en) |
WO (1) | WO2010030667A2 (en) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP6415535B2 (en) * | 2013-04-05 | 2018-10-31 | エスシーファーマシューティカルズ インコーポレイテッド | Pharmaceutical formulation for subcutaneous administration of furosemide |
CN108295264A (en) * | 2018-03-28 | 2018-07-20 | 五邑大学 | The application of polyvinylpyrrolidone k12 |
EP3906019A1 (en) | 2019-01-04 | 2021-11-10 | SQ Innovation AG | Pharmaceutical compositions of furosemide and uses thereof |
EP3917495A1 (en) | 2019-01-31 | 2021-12-08 | scPharmaceuticals Inc. | Concentrated liquid pharmaceutical formulations of furosemide and methods of administering the same |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6613332B1 (en) * | 1991-06-21 | 2003-09-02 | The University Of Cincinnati | Oral administration of therapeutic proteins |
US6350470B1 (en) * | 1998-04-29 | 2002-02-26 | Cima Labs Inc. | Effervescent drug delivery system for oral administration |
EP2127642A3 (en) * | 1998-08-13 | 2010-02-24 | Cima Labs, Inc. | Microemulsions as solid dosage forms for oral administration |
US6228400B1 (en) * | 1999-09-28 | 2001-05-08 | Carlsbad Technology, Inc. | Orally administered pharmaceutical formulations of benzimidazole derivatives and the method of preparing the same |
WO2001037838A1 (en) * | 1999-11-24 | 2001-05-31 | Wakamoto Pharmaceutical Co., Ltd. | Ophthalmic aqueous preparation |
AU2001241730B2 (en) * | 2001-02-23 | 2007-03-15 | Cima Labs Inc. | Emulsions as solid dosage forms for oral administration |
DE102004021281A1 (en) * | 2004-04-29 | 2005-11-24 | Boehringer Ingelheim Vetmedica Gmbh | Use of meloxicam formulations in veterinary medicine |
-
2009
- 2009-09-09 CA CA2735660A patent/CA2735660C/en not_active Expired - Fee Related
- 2009-09-09 MX MX2011002084A patent/MX340669B/en active IP Right Grant
- 2009-09-09 EP EP09792369.2A patent/EP2334302B1/en not_active Withdrawn - After Issue
- 2009-09-09 WO PCT/US2009/056362 patent/WO2010030667A2/en active Application Filing
- 2009-09-09 JP JP2011526303A patent/JP5661630B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
MX340669B (en) | 2016-07-20 |
WO2010030667A3 (en) | 2010-07-22 |
JP2012502065A (en) | 2012-01-26 |
CA2735660C (en) | 2017-05-30 |
CA2735660A1 (en) | 2010-03-18 |
JP5661630B2 (en) | 2015-01-28 |
EP2334302A2 (en) | 2011-06-22 |
WO2010030667A2 (en) | 2010-03-18 |
MX2011002084A (en) | 2011-03-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ZA201104336B (en) | Pharmaceutical compounds | |
GB0816372D0 (en) | Pharmaceutical compounds | |
GB0820819D0 (en) | Pharmaceutical compounds | |
GB0801416D0 (en) | Pharmaceutical compounds | |
ZA201006029B (en) | Pharmaceutical dosage form | |
EP2320907A4 (en) | Therapeutic compounds | |
IL209895A0 (en) | Compounds for treating beta-amyloidoses | |
GB0816371D0 (en) | Pharmaceutical compounds | |
IL200020A0 (en) | Dosage regimen for comt inhibitors | |
EP2268285A4 (en) | Therapeutic compounds | |
GB0806794D0 (en) | Therapeutic compounds | |
GB0813740D0 (en) | Therapeutic compounds | |
GB0812969D0 (en) | Pharmaceutical compounds | |
ZA200903858B (en) | Pharmaceutical dosage form | |
PL2271618T3 (en) | Pharmaceutical compounds | |
GB0816370D0 (en) | Pharmaceutical compounds | |
GB0804755D0 (en) | Therapeutic compounds | |
GB0810857D0 (en) | Pharmaceutical compounds | |
EP2285385A4 (en) | siRNA COMPOUNDS FOR INHIBITING NRF2 | |
EP2334302B1 (en) | Dosage forms for weakly ionizable compounds | |
EP2265260A4 (en) | Solid dosage form for treating headaches | |
HK1156250A1 (en) | Unit dosage of apadenoson | |
PL2519233T3 (en) | Pharmaceutical composition for treating alcohol dependency | |
GB0908905D0 (en) | Pharmaceutical compounds | |
EP2276769A4 (en) | New peptidomimetic compounds |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20110411 |
|
AK | Designated contracting states |
Kind code of ref document: A2 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK SM TR |
|
AX | Request for extension of the european patent |
Extension state: AL BA RS |
|
REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1158980 Country of ref document: HK |
|
17Q | First examination report despatched |
Effective date: 20161007 |
|
GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
INTG | Intention to grant announced |
Effective date: 20171011 |
|
GRAS | Grant fee paid |
Free format text: ORIGINAL CODE: EPIDOSNIGR3 |
|
GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
PUAC | Information related to the publication of a b1 document modified or deleted |
Free format text: ORIGINAL CODE: 0009299EPPU |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN |
|
AK | Designated contracting states |
Kind code of ref document: B1 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK SM TR |
|
AX | Request for extension of the european patent |
Extension state: AL BA RS |
|
REG | Reference to a national code |
Ref country code: GB Ref legal event code: FG4D |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: EP Ref country code: CH Ref legal event code: PK Free format text: DIE ERTEILUNG WURDE VOM EPA WIDERRUFEN. |
|
DB1 | B1 document deleted |
Effective date: 20180302 |
|
18W | Application withdrawn |
Effective date: 20180222 |
|
REG | Reference to a national code |
Ref country code: LU Ref legal event code: HK Effective date: 20180328 |
|
REG | Reference to a national code |
Ref country code: AT Ref legal event code: REF Ref document number: 980352 Country of ref document: AT Kind code of ref document: T Effective date: 20180415 |
|
REG | Reference to a national code |
Ref country code: IE Ref legal event code: FG4D |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R096 Ref document number: 602009051381 Country of ref document: DE |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R107 Ref document number: 602009051381 Country of ref document: DE |
|
REG | Reference to a national code |
Ref country code: AT Ref legal event code: REZ Ref document number: 980352 Country of ref document: AT Kind code of ref document: T Effective date: 20180321 |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: PK Free format text: DAS LOESCHDATUM WURDE ERGAENZT / LE CHAMP DATE DE RADIATION A ETE COMPLETE / LA DATA DI CANCELLAZIONE E STATA COMPLETATA |